Kovac M, Woolley C, Ribi S, Blattmann C, Roth E, Morini M, et al. Germline RET variants underlie a subset of paediatric osteosarcoma. Journal of medical genetics. 2021;58(1):20-4. doi: 10.1136/jmedgenet-2019-106734.
Kelley LM, Schlegel M, Hecker-Nolting S, Kevric M, Haller B, Rossig C, et al. Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020:JCO1900827. doi: 10.1200/jco.19.00827.
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, et al. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European journal of cancer (Oxford, England : 1990). 2020;138:212-24. doi: 10.1016/j.ejca.2020.07.019.
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, et al. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in brief. 2020;32:106227. doi: 10.1016/j.dib.2020.106227.
Calaminus G, Jenney M, Hjorth L, Baust K, Bernstein M, Bielack S, et al. Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. JMIR research protocols. 2019;8(8):e14406. doi: 10.2196/14406.
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European journal of cancer (Oxford, England : 1990). 2019;109:36-50. doi: 10.1016/j.ejca.2018.11.027.
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310.
Schuster AJ, Kager L, Reichardt P, Baumhoer D, Csoka M, Hecker-Nolting S, et al. High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients. Sarcoma. 2018;2018:1632978. doi: 10.1155/2018/1632978.
Ferrari S, Bielack SS, Smeland S, Longhi A, Egerer G, Sundby Hall K, et al. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori. 2018;104(1):30-6. doi: 10.5301/tj.5000696.
Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen A, et al. PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. European journal of cancer (Oxford, England : 1990). 2018;103:227-37. doi: 10.1016/j.ejca.2018.08.007.
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310.
Smida J, Xu H, Zhang Y, Baumhoer D, Ribi S, Kovac M, von Luettichau I, Bielack S, O'Leary VB, Leib-Mösch C, Frishman D, Nathrath M: Genome-wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma. Int J Cancer. 2017 May 11. doi: 10.1002/ijc.30778. [Epub ahead of print]
Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, Debatin KM, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Frühwald MC, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Körholz D, Koscielniak E, Kramm CM, Kuhlen M, Kulozik AE, Lamottke B, Leuschner I, Lohmann DR, Meinhardt A, Metzler M, Meyer LH, Moser O, Nathrath M, Niemeyer CM, Nustede R, Pajtler KW, Paret C, Rasche M, Reinhardt D, Rieß O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, von Bueren AO, Vorwerk P, Witt O, Wlodarski M, Wössmann W, Zenker M, Zimmermann S, Pfister SM, Kratz CP: Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 173(4):1017-1037, 2017
Longhi A, Bielack SS, Grimer R, Whelan J, Windhager R, Leithner A, Gronchi A, Biau D, Jutte P, Krieg AH, Klenke FM, Grignani G, Donati DM ,Capanna R, Casanova J, Gerrand C, Bisogno G, Hecker-Nolting S,De Lisa M , D’Ambrosio L, Willegger M5, Scoccianti G, Ferrari S: Extraskeletal osteosarcoma: a European Musculoskeletal Oncology Society (EMSOS) study on 266 patients, Eur J Cancer 74:9-16, 2017
Kager L, Tamamyan G, Bielack S: Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol 13:357-368, 2017
Bielack S, Hecker-Nolting S, Blattmann C, Kager L: Advances in the management of osteosarcoma. F1000Res. 2016 Nov 25;5:2767. (F1000 Faculty Rev, doi: 10.12688/f1000research.9465.1)
Ferrari A, Dirksen U, Bielack S: Sarcomas of Soft Tissue and Bone. Prog Tumor Res 43:128-41, 2016
Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KL, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PC, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MC, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS: Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 17(10):1396-1408, 2016
Kaatsch P, Strothotte J, Becker C, Bielack SS, Dirksen U, Blettner M: Pediatric bone tumors in Germany from 1987 to 2011: incidence rates, time trends and survival. Acta Oncol. 55(9-10):1145-1151, 2016
Bielack S, Kager L, Hecker-Nolting S, Blattmann C, Nathrath M, von Kalle T, Wirth T, Jürgens H : Therapie von Kindern, Jugendlichen und jungen Erwachsenen mit Osteosarkom. Journal Onkologie 2016
Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F; Ferrari S, Fiocco M; Fleuren E, Gaspar N, Gelderblom H; Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley M; McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P; Potratz J, Redini F, Richter GH; Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G; Bielack SS: The ENCCA‑WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report. Clin Sarcoma Res (2016) 6:3, doi: 10.1186/s13569-016-0043-5. eCollection 2016
Bielack S: ABSTRACT REVIEWS ECC: Targeting Osteosarcoma: What is the difference between adult and paediatric patients? EMJ Oncology November 2015:74-75, 2015
Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M, Krieg A, Andreou D, Tunn PU, Dürr HR, Rechl H, Schaser KD, Melcher I, Stefan E.G. Burdach, Kulozik A, Specht K, Heinimann K, Fulda S, Bielack S, Jundt G, Tomlinson I, Korbel JO, Nathrath M, Baumhoer D: Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun. 2015;6:8940; doi: 10.1038/ncomms9940.
Isakoff M, Bielack SS, Meltzer P, Gorlick R: Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol 33:3029-35, 2015
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M: EURAMOS-1 investigators. MAP plus maintenance pegylated interferon-2b (MAPifn) versus MAP alone in patients with resectable high grade osteosarcoma and good histological response to preoperative MAP: First results of the EURAMOS 1 Good Response randomized controlled trial. J Clin Oncol 33(20):2279-87, 2015
Kager L, Diakos C, Bielack S: Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma. Expert Opin Drug Metab Toxicol 11:1025-1028, 2015
Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, Gronchi A, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J: Mesenchymal chondrosarcoma: prognostic factors and outcome. A European Musculoskeletal Oncology Society study. Eur J Cancer 51:374-81, 2015
Tamamyan G, Dominkus M, Lang S, Diakos C, Mittheisz E, Horcher E, Holter W, Zoubek A, Bielack S, Kager L: Multiple relapses in high-grade osteosarcoma: When to stop aggressive therapy? Pediatr Blood Cancer 62:529–530, 2015
Zils K, Klingebiel T, Behnisch W, Mueller HL, Schlegel P, Fruehwald M, Suttorp M, Simon T, Werner M, Bielack S: Osteosarcoma in Patients with Rothmund-Thomson Syndrome. Pediatr Hematol Oncol 32:32-40, 2015
Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau C, Letson GD, Meyer J, Meyers P, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M, on behalf of the EURAMOS collaborators: EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 26: 407–414, 2015
Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau C, Letson GD, Meyer J, Meyers P, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M; on behalf of the EURAMOS collaborators. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 2014 Nov 24. pii: mdu526
Hecker-Nolting S, Bielack S: Therapie primär maligner Knochentumoren, Tumor Diagnostik & Therapie, TumorDiagn u Ther 35(08): 472-475, 2014
ESMO/European Sarcoma Network Working Group. Casali PG, Blay JY, Bertuzzi A, Bielack S, Bjerkehagen B, Bonvalot S, Boukovinas I, Bruzzi P, Dei Tos AP, Dileo P, Eriksson M, Fedenko A, Ferrari A, Ferrari S, Gelderblom H, Grimer R, Gronchi A, Haas R, Hall KS, Hohenberger P, Issels R, Joensuu H, Judson I, Le Cesne A, Litière S, Martin-Broto J, Merimsky O, Montemurro M, Morosi C, Picci P, Ray-Coquard I, Reichardt P, Rutkowski P, Schlemmer M, Stacchiotti S, Torri V, Trama A, Van Coevorden F, Van der Graaf W, Vanel D, Wardelmann E, Bolle S, Capanna R, Delaney T, Doglietto F, Fossati P, Jeys L, Kasper B, Leithner A, Radaelli S, Scheipl S, Tamborini E, Uhl M, Vleggert-Lankamp CL. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii113-23. doi: 10.1093/annonc/mdu256
Hospach T, Bielack S, v. Kalle T: Nächtliche Schmerzen am Bewegungsapparat: Die Anamnese weist den Weg zur Diagnose, Kinderärztliche Praxis 85, 174 – 176, 2014
Sorg B, Kevric M, Hecker-Nolting S, Kempf-Bielack B, Daniels K, Bielack S: Osteosarkome, Onkologische Pflege 3:49-58, 2014
Bielack S, Kager L: Multimodale Therapie des Osteosarkoms. Gesicherte Erkenntnisse und offene Fragen. JATROS Onkologie 3/14:136-139, 2014
Wilhelm M, Dirksen U, Bielack S, Whelan JS, Lewis IJ, Jürgens H, Ferrari S, Sundby Hall K, Cleton-Jansen AM, Stark D: ENCCA WP17-WP7 consensus paper on Teenagers and Young Adults (TYA) with bone sarcomas, Ann Oncol 25(8):1500-5, 2014; doi:10.1093/annonc/mdu153 2014
Bielack S, Hecker-Nolting S, Kevric M, Jürgens H: More on Osteosarcoma and Phyllodes tumor, J Pediatr Hematol Oncol. 2014 Sep 26
Kager L, Bielack S: Chemotherapeutische Konzepte bei Knochensarkomen, Unfallchirurg 117:517–522, 2014
Anninga J, Cleton-Jansen AM, Hassan B, Amary MA, Baumhoer D, Blay JY, Brugieres L, Ferrari S, Jürgens J, Kempf-Bielack B, Kovar H, Myklebost O, Nathrath M, Picci P, Riegman P, Schilham MW, Soliman R, Stark DP, Strauss S, Sydes M, Tarpey P, Thomas D, Whelan J, Wilhelm M, Zamzam M, Gelderblom H, Bielack S: Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology, Clinical Sarcoma Research 4:4, 2014
Tallen G, Bielack S, Henze G, Horneff G, Korinthenberg R, Lawrenz B, Niehues T, Peitz J, Placzek R, Schmittenbecher P, Schönau E, Wessel L, Wirth T, Mentzel HJ, Creutzig U: Musculoskeletal Pain: A New Algorithm for Differential Diagnosis of a Cardinal Symptom in Pediatrics. Klin Padiatr. 226(2):86-98, 2014
Brecht IB, Bremensdorfer C, Schneider DT, Frühwald MC, Offenmüller S, Mertens R, Vorwerk P, Koscielniak E, Bielack S, Benesch M, Hero B, Graf N, On Schweinitz D, Kaatsch P.: Rare malignant pediatric tumors registered in the German Childhood Cancer Registry 2001-2010. Pediatr Blood Cancer 61(7):1202-9, 2014
Zils K, Wirth T, Loff S, Biskup S, von Kalle T, Bielack S: Multiple Metachronous Osteosarcomas in a Patient with Li-Fraumeni Syndrome. Pediatr Hematol Oncol Pediatr Hematol Oncol 31(4):359-61, 2014
Kager L, Bielack S: Biologie, Diagnostik, systemische und chirurgische Therapie. Osteosarkome. SPECTRUM ONKOLOGIE 3:30-33, 2013
Bielack S, Kevric M: High BMI at Diagnosis Is Not Associated With Inferior Survival in Patients With Osteosarcoma. A report from the Cooperative Osteosarcoma Study Group Pediatr Blood Cancer. 2014 May;61(5):952. doi: 10.1002/pbc.24817. Epub 2013 Oct 11
Zils K, Bielack S: Osteosarcoma after Bone Marrow Transplantation - still a challenge J Pediatr Hematol Oncol 2013 Aug 7
Rossig C, Juergens H, Schrappe M, Moericke A, Henze G, von Stackelberg A, Reinhardt D, Burkhardt B, Woessmann W, Zimmermann M, Gadner H, Mann G, Schellong G, Mauz-Koerholz C, Dirksen U, Bielack S, Berthold F, Graf N, Rutkowski S, Calaminus G, Kaatsch P, Creutzig U: Effective Childhood Cancer Treatment – The impact of large scale clinical trials inGermany and Austria, Pediatr Blood Cancer 60:1574–1581, 2013
Zils K, Bielack S, Wilhelm M, Werner M, Schwarz R, Windhager R, Hofmann-Wackersreuther G, Andus T, Kager L, Kuehne T, Reichardt P, von Kalle T: Osteosarcoma of the mobile spine. Ann Oncol. 24(8):2190-2195, 2013
Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, Kager L, Kühne T, Sydes M, Gelderblom H, Ferrari S, Picci P, Smeland S, Eriksson M, Petrilli S, Bleyer A, Thomas DM: Benefits and adverse events in younger versus older patients receiving (neo)-adjuvant chemotherapy for osteosarcoma: findings from a 4,403 patient meta-analysis. J Clin Oncol 31(18):2303-12, 2013
Bielack S, Kempf-Bielack B, Von Kalle T, Schwarz R, Wirth T, Kager L, Whelan J: Controversies in childhood osteosarcoma. Minerva Pediatr 65(2):125-148, 2013
Wilhelm M, Bielack S, Zils K, Gosheger G, Friedel G, Lehner B, von Kalle T: Primary Pulmonary Metastatic Osteosarcoma: To Stop or Not to Stop, That is the Question Journal of Adolescent and Young Adult Oncology, 2: 38-41, 2013
Nitz A, Kontopantelis E, Bielack S, Koscielniak E, Klingebiel T, Langer T, Paulides M: Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett 5(1):311-315, 2013
Bielack S: Comment on 'Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?' Br J Cancer 107(3):583, 2012 (letter)
Bielack S, Morland B, Mayor S: Recent trials in osteosarcoma and their implications for future studies Cancerworld May/June 2012, 13-20, 2012
Zils K, Ebner F, Ott M, Müller J, Baumhoer D, Greulich M, Rehnitz D, Rempen A, Schaetzle S, Wilhelm M, Bielack S: Extraskeletal osteosarcoma of the breast in an adolescent girl. J Pediatr Hematol Oncol 34:e261-e263, 2012
Zils K, Wilhelm M, Reeh T, Bielack S: Bullous variant of acral erythema in a child after high-dose methotrexate Pediatr Hematol Oncol 29:378-9, 2012
Baumhoer D, Elsner M, Smida J, Zillmer S, Rauser S, Schoene C, Balluff B, Bielack S, Jundt G, Walch A, Nathrath M: CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients. Oncotarget 2:970-975, 2012
Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werlé N, Gelderblom H, Hassan B, Jürgens H, Koster J, Kovar H, Lankester AC, Lewis IJ, Myklebost O, Nathrath MHM, Picci P, Whelan JS, Hogendoorn PCW, Bielack S: Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology Journal of Adolescent and Young Adult Oncology. 1:118-123, 2011
Bielack S: JSCO University 12: Bone, soft tissue, and skin cancers: Year in review in Europe - Bone sarcomas from a pediatric perspective. The Journal of Japan Society of Clinical Oncology 46(3):1402-1406, 2011
Kager L, Bielack S: Mifamurtide - Trade name: Mepact (Short Survey), [Mifamurtid: Handelsname: Mepact (D, A, CH)], Internistische Praxis 51(4):899-901, 2011 Gynäkologische Praxis 35 (4): 771-773, 2011, Tägliche Praxis 52 (4) 899-901, 2011, Pädiatrische Praxis 77 (4) 741-743, 2011, Chirurgische Praxis 74 (1) 173-175, 2011
Zils K, Bielack S: Therapeutic management of osteosarcoma, Hospital Pharmacy Europe 56:51-54, 2011
Baumhoer D, Smida J, Specht K, Bink K, Quintanilla-Martinez L, Rosemann M, Siggelkow H, Nathrath WB, Atkinson MJ, Bielack S, Jundt G, Nathrath M: Aberrant expression of the HER-2 oncogene is not a common feature in osteosarcoma , Hum Pathol 42:859-66, 2011
Bielack S, Marina N, Bernstein M: High-intensity focused ultrasound (HIFU) is not indicated for treatment of primary bone sarcomas, Cancer 117:2822, 2011 (letter)
Ritter J, Zils K, Bielack S: Osteosarkome bei Kindern und Jugendlichen, Pädiatrie up2date 6(1): 79-104, 2011
Paulides M, Stöhr W, Laws HJ, Graf N, Lakomek M, Berthold F, Schmitt K, Niggli F, Jürgens H, Bielack S, Koscielniak E, Klingebiel T, Langer T: Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: A report from the Late Effects Surveillance System. Vaccine 29:1565-1568, 2011
Franke, M, Hardes J, Helmke K, Jundt G, Jürgens H,Kempf-Bielack B, Kevric M, Tunn PU, Werner M, Bielack S: Solitary Skeletal Osteosarcoma Recurrence. Findings From The Cooperative Osteosarcoma Study Group (COSS), Pediatr Blood Cancer 56:771–776, 2011
Ellegast J, Barth TFE, Schulte M, Bielack S, Schmid M, Mayer-Steinacker R: Diagnosis in Oncology: Metastasis of osteosarcoma after 16 years. J Clin Oncol 29(3):e62-6; 2011
Andreou D, Bielack S, Carrle D, Kevric M, Kotz R, Winkelmann W, Jundt G, Werner M, Fehlberg S, Kager L, Kühne T, Lang S, Dominkus M, Exner GU, Hardes J, Hillmann A, Ewerbeck V, Heise U, Reichardt P, Tunn PU: The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols, Ann Oncol 22: 1228-1235, 2011
Kager L, Zoubek A, Dominkus M, Lang S,Bodmer N, Jundt G, Klingebiel T, Jürgens H, Gadner H, Bielack S: Osteosarcoma in very young children. Experience of the Cooperative Osteosarcoma Study Group. Cancer 116:5316-24, 2010
Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W, Dierkes C, Burdach S, Jundt G, Atkinson MJ, Nathrath M: Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 16:4256-4267, 2010
Kager L, Pöttschger U, Bielack S: Review of mifamurtide in the treatment of patients with osteosarcoma, Ther Clin Risk Manag 6:279-286, 2010
Ritter J, Bielack S: Osteosarcoma (symposium article), Ann Oncol 21 (Supplement 7): vii320–vii325, 2010
Paulides M, Stöhr W, Laws HJ, Graf N, Lakomek M, Berthold F, Schmitt K, Niggli F, Jürgens H, Bielack S, Koscielniak E, Klingebiel T, Langer T: Immunity against tetanus and diphtheria after childhood sarcoma treatment. Klin Padiatr 222:196, 2010
Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Supplement 5): v204–v213, 2010
Bielack S: Editorial comment: Osteosarcoma: Time to move on? Eur J Cancer 46:1942-1945, 2010
Bielack S, Carrle D, Friedel G: Indications for CT-guided percutaneous thoracic biopsy. Comment on: AJR Am J Roentgenol. 2009 Nov;193(5):W430-6. AJR Am J Roentgenol 194:[web]W462, 2010 (letter); author reply W463
Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein, M: The Role of Interferons in the Treatment of Osteosarcoma, Pediatr Blood Cancer 54:350-354, 2010
Kager L, Kempf-Bielack B, Bielack S: Synchronous and Metachronous Lung Metastases in High-grade Osteosarcoma. Jpn J Clin Oncol 40(1):94-5, 2010 (letter)
Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S: The role of radiotherapy in osteosarcoma. Cancer Treat Res 152:147-165, 2009
Carrle D, Bielack S: Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res 152:165-184, 2009
Bielack S, Jürgens H, Jundt G, Kevric M, Kühne T, Reichardt P, Zoubek A, Werner M, Winkelmann W, Kotz R: Osteosarcoma: The COSS Experience. Cancer Treat Res 152:289-308, 2009
Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, Butterfass-Bahloul T, Calaminus G, Bernstein M: International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience, Cancer Treat Res 152: 339-353, 2009
Bielack S, Carrle D, Casali PG on behalf of the ESMO Guidelines Working Group
Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (Supplement 4): iv137–iv139, 2009
Heinsohn S, Szendroi M, Bielack S, Zur Stadt U, Kabisch H: Evaluation of SV40 in osteosarcoma and healthy population: A Hungarian-German study, Oncology Rep 21(2):289-297, 2009
Bielack S, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, Kevric M, Jundt G, Kühne T, Maas R, Schwarz R, Zoubek A, Jürgens H: Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive Cooperative Osteosarcoma Study Group (COSS) patients. J Clin Oncol 27:557-65, 2009
Bielack S: Pediatric extraskeletal osteosarcoma. Pediatr Radiol 38:1033, 2008 (letter)
Bielack S: Developments in the Treatment of Paediatric Extraskeletal Osteosarcoma. European Pediatrics 2:48-49, 2008
Bielack S, Carrle D: State-of-the-art approach in selective curable tumors: bone sarcoma, Ann Oncol 19 Suppl 7:vii1-vii6, 2008
Bielack S, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS, Reaman GH
Osteosarcoma: The same old drugs or more? (letter to: Meyers et al - Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.) J Clin Oncol 26:3102-3103, 2008 (letter)
Bielack S, Carrle D, Hardes J, ,Schuck A, Paulussen M: Bone Tumors in Adolescents and Young Adults, Curr Treat Options Oncol 9:67-80, 2008
Kersting C, Agelopoulos K, Schmidt H, Korsching E, August C, Gosheger G, Dirksen U, Juergens H, Winkelmann W, Brandt B, Bielack S, Buerger H, Gebert C:
Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas. Genes Chromosomes Cancer 47:657-664, 2008
Bielack S, Carrle D, Jost L: ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2:ii94-6, 2008
Dantonello T, Int-Veen C, Leuschner I, Schuck A, Furtwaengler R, Claviez A, Schneider DT, Klingebiel T, Bielack SS, Koscielniak E: Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults. experiences of the CWS- and COSS-study groups, Cancer 112:2424–31, 2008
Jasnau S, Meyer U, PotratzJ, Jundt G, Kevric M, Joos UK, Jürgens H, Bielack S:
Craniofacial osteosarcoma. Experience of the cooperative German–Austrian–Swiss osteosarcoma study group. Oral Oncol 44:286-294, 2008
Carrle D, Dantonello T, Bielack S: Pan-European Sarcoma Trials: Moving Forward in a Climate of Increasing Economic and Regulatory Pressure, Sarcoma, vol. 2007, Article ID 76405, 7 pages, 2007. doi:10.1155/2007/76405
Kersting C, Gebert C, Agelopoulos K, Schmidt H, van Diest PJ, Juergens H, Winkelmann W, Kevric M, Gosheger G, Brandt B, Bielack S, Buerger H:
Epidermal Growth Factor Receptor (EGFR) expression in high grade osteosarcomas is associated with a good clinical outcome, Clin Cancer Res 13:2998-3005, 2007
Bielack S, Kager L, Zoubek A: Skip metastases in osteosarcoma. Electronic letter to: Heck RK Jr., Peabody TD, Simon MA: Staging of Primary Malignancies of Bone (CA Cancer J Clin 2006; 56: 366-375). CA Cancer J Clin 2007 (letter)
(e-letter 12 January 2007, www.caonline.amcancersoc.org/cgi/eletters/56/6/366)
Paulides M, Dörr HG, Stohr W, Bielack S, Koscielniak E, Klingebiel T, Jürgens H, Bolling T, Willich N, Sauer R, Langer T, Beck JD: Thyroid function in pediatric and young adult patients after sarcoma therapy: A report from the Late Effects Surveillance System, Clin Endocrinol (Oxf) 66:727-31, 2007
Heinsohn S, Evermann U, Zur Stadt U, Bielack S, Kabisch H: Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol 30:1205-14, 2007
Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, Langer T, Beck JD
Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System.Pediatr Blood Cancer 48:447-452, 2007
Stöhr W, Paulides M, Bielack S, Jurgens H, Koscielniak E, Rossi R, Langer T, Beck JD: Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer 48:140-7, 2007
Carrle D, Bielack S: Diagnostik und multimodales Therapiekonzept des Osteosarkoms. Ärztliches Journal Onkologie 3:34-38, 2007
Stiller CA,Bielack S, Jundt G, Steliarova-Foucher E: Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project, Eur J Cancer 42: 2124–2135, 2006
Eselgrim M, Grunert H, Kühne T, Zoubek A, Kevric M, Bürger H, Jürgens H, Mayer-Steinacker R, Gosheger G, Bielack S: Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer 47:42-50, 2006
Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R, Exner GU, Franzius C, Lang S, Maas R, Jürgens H, Gadner H, Bielack S: Skip metastases in osteosarcoma. Experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 24:1535-1541, 2006
Hauben EI, Bielack S, Grimer R, Jundt G, Reichardt P, Sydes M, Taminiau AH, Hogendoorn PC: Clinico-histologic parameters of osteosarcoma patients with late relapse. Eur J Cancer 42:460-466, 2006
Paulides M, Kremers A, Stöhr W, Bielack S, Jürgens H, Treuner J, Beck JD,Langer T and German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH): Prospective Longitudinal Evaluation of Doxorubicin-Induced Cardiomyopathy in Sarcoma Patients: A Report of the Late Effects Surveillance System (LESS), Pediatr Blood Cancer 46:489-495, 2006
Paulides M, Stohr W, Bielack S, Jürgens H, Koscielniak E, Klingebiel T, Zimmermann R, Stachel D, Langer T, Beck JD: Prospective evaluation of hepatitis B, C and HIV infections as possible sequelae of antineoplastic treatment in paediatric sarcoma patients: A report from the Late Effects Surveillance System.
Oncol Rep 15:687-691,2006
Carrle D, Bielack S: Current strategies of chemotherapy in osteosarcoma.
International Orthopaedics 30:445-51, 2006
Potratz J, Zoubek A, Bielack S: Maligne Knochentumoren bei Kindern und Jugendlichen (Leitthema) Monatsschr Kinderheilkd 154:10-19, 2006
Potratz J, Bielack S: Osteosarkome bei Kindern und Jugendlichen. Verbesserte Prognose durch multimodale Therapiekonzepte, pädiatrie hautnah 18:66-72, 2006
Grimer RJ, Bielack S, Flege S, Cannon SR, Foleras G, Sokolov T, Andreeff I, Taminiau A, Dominkus M, San Julian M, Kollender Y, Gosheger G: Periosteal osteosarcoma – a European review of outcome. Eur J Cancer 41:2806-2811, 2005
Kempf-Bielack B, Bielack S, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K: Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559-568, 2005
Goldstein-Jackson SY, Gosheger G, Delling G, Berdel WE, Exner GU, Jundt G, Machatschek JN, Zoubek A, Jürgens H, Bielack S: Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma.
J Cancer Res Clin Oncol 131:520-526, 2005
Daecke W, Bielack S, Martini AK, Ewerbeck V, Jürgens H, Kotz R, Winkelmann W, Kabisch H, Kevric M, Bernd L: Osteosarcoma of the hand and forearm: Experience of the Cooperative Osteosarcoma Study Group. Ann Surg Oncol, 12:322-331, 2005
Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD; German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology: Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 23:201-207, 2005
Bielack S, Jürgens H: Surgical expertise and outcome in osteosarcoma trials.
J Clin Oncol 22:2511-2512, 2004 (letter)
Kreuter M, Bieker R, Bielack S, Auras T, Buerger H, Gosheger G Jürgens H, Berdel WE, Mesters RM: Prognostic relevance of increased angiogenesis in osteosarcoma, Clin Cancer Res Vol. 10:8531–8537, 2004
Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC: High-dose methotrexate-induced nephrotoxicity: Incidence in osteosarcoma. Patients, treatment and outcome. Cancer 100:2222-2232, 2004
Langer T, Stöhr W, Bielack S, Paulussen M, Treuner J, Beck JD: Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 42:373-379, 2004 (Journal bis 2003 unter dem Namen “Medical and Pediatric Oncology)
Leidinger B, Bielack S, Koehler G, Vieth V, Winkelmann W, Gosheger G: High level of beta-hCG simulating pregnancy in recurrent osteosarcoma – case report and review of literature. J Cancer Res Clin Oncol 130(6):357-61, 2004
Bielack S, Potratz J, Jürgens J: Osteosarkome bei Kindern, Jugendlichen und Erwachsenen: Diagnostik, interdisziplinäre Therapie und Nachsorge, Journal Onkologie 4:10-18, 2004
Flege S, Bielack S: Ziele und Ergebnisse der COSS-Studien. Handchir Mikrochir Plast Chir 36: 282-288, 2004
Bielack S, Machatschek JN, Flege S, Jürgens H: Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 5:1243-56, 2004
Werner M, Delling G: Chemotherapy-induced changes in high grade central osteosarcomas-experiences gained through the assignment as reference-pathologists of the COSS-studies. Pathologe. 2004 Nov;25(6):445-53.
Bielack S, Hunold A, Kempf-Bielack B, Jürgens H: Maligne Knochentumoren.
Kinder- und Jugendmedizin 3:1-58, 2003
Flege S, Kuhlen M, Paulussen M, Bielack S, Jürgens H: Operative Therapie primär maligner Knochentumoren. Orthopäde 32: 940-948, 2003
Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack S: Primary metastatic osteosarcoma: Presentation and outcome of 202 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group (COSS) protocols. J Clin Oncol 21:2011-2018, 2003
Korrespondenz: In Reply to Brockstein B: Metastatic osteosarcoma: A curable advanced malignancy. J Clin Oncol 22:5017, 2004 : J Clin Oncol 22:5017-5018, 2004
Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik M, Berdel WE, Jürgens H, Exner GU, Reichardt P, Mayer-Steinacker R, Ewerbeck V, Kotz R, Winkelmann W, Bielack S:
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 21:334-341, 2003
Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Ritschl P, Windhager R, Dominkus M, Saeter G, Bauer H, Meller I, Szendroi M, Folleras G, San-JulianM, v.d. Eijken J: Osteosarcoma over the age of fourty. Eur J Cancer 39:157-163, 2003
Bielack S, Rerin J, Dickerhoff R, Dilloo D, Kremens B, v.Stackelberg A, Vormoor J, Jürgens H: Osteosarcoma after allogeneic bone marrow transplantation. A report of four cases from the Cooperative Osteosarcoma Study Group COSS.
Bone Marrow Transplant 31:353-359, 2003
Bielack S, Tabone MD: Letter to the editor (Re.Hamre MR, Severson RK, Chub P, Lucas DR, Thomas RL, Mott MP: Osteosarcoma as a second malignant neoplasm, Radiother Oncol 2002; 65:153-157 Oncol). Radiother Oncol 68:89, 2003 (letter)
Creutzig U, Henze G, Bielack S, Herold R, Kaatsch P, Klussmann JH, Graf N, Reinhardt D, Schrappe M, Zimmermann M, Jürgens H: Krebserkrankungen bei Kindern: Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Deutsches Ärzteblatt 100(13)A:842-852, 2003
Bielack S, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K:
Prognostic factors in high-grade osteosarcoma of the extremities or trunk. An analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 20: 776-790, 2002
Editorial (P. Meyers): Prognostic Factors for Sarcomas: Hard and Soft. J Clin Oncol 20:627-629, 2002; Korrespondenz: J Clin Oncol 20:2910, 2002
Ozaki T, Flege S, Liljenqvist U, Hillmann A, Delling G, Salzer-Kuntschik M, Jürgens H, Kotz R, Winkelmann W, Bielack S: Osteosarcoma of the spine: Experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer 94: 1069-1077 2002
Franzius C, Schuck A, Bielack S: High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients with Osteosarcoma and Bone Metastases. J Clin Oncol 20 1953-1954, 2002 (letter)
Ozaki T, Wai D, Schaefer KL, Buerger H, Flege S, Lindner N, Kevric M, Diallo R, Bankfalvi A, Brinkschmidt C, Juergens H, Winkelmann B, Dockhorn-Dworniczak B, Bielack S, Poremba C: Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 102:355-65, 2002
Franzius C, Bielack S, Flege S, Sciuk J, Jurgens H, Schober O: Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 43(8):1012-7, 2002
Langer T, Führer M, Stöhr W, Dörffel W, Dörr HG, Bielack S, Rossi R, Kaatsch P, Beck JD: Die Überlebenden einer Krebserkrankung im Kindesalter Nachsorge und Spätfolgen nach erfolgreicher Therapie. Monatsschr Kinderheilkd 150(8):942-953, 2002
Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Jurgens H, Schober O:
High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin-Nuclear Medicine 40:215-20, 2001
Sauerbrey A, Bielack S, Kempf-Bielack B, Zoubek A, Paulussen M, Zintl F.
High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma.
Bone Marrow Transplant 27:933-937, 2001
Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, Bielack S, Jurgens H, Schober O: FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12:479-486, 2001
Heinsohn S, Scholz RB, Weber B, Wittenstein B, Werner M, Delling G, Kempf-Bielack B, Setlak P, Bielack S, Kabisch H: SV40 sequences in human osteosarcoma of German origin. Anticancer Res 20:4539-4545, 2000
Bielack S, Flege S, Kempf-Bielack B: Behandlungskonzept des Osteosarkoms.
Onkologe 6:747-759, 2000
Bielack S, Kempf-Bielack B, Heise U, Schwenzer D, Winkler K: Combined modality treatment for osteosarcoma occurring as a second malignant disease. J Clin Oncol 17:1164-1174, 1999
Bielack S, Schroeders A, Fuchs N, Bacci G, Bauer HCF, Mapeli S, Tomeno B, Winkler K: Malignant fibrous histiocytoma of bone: a retrospective EMSOS study of 125 cases. European Musculo-Skeletal Oncology Society. Acta Orthop Scand 70:353-60, 1999
Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, Exner U, Fuchs N, Graf N, Heise U, Helmke K, von Hochstetter AR, Jürgens H, Maas R, Münchow N, Salzer-Kuntschik M, Treuner J, Veltmann U, Werner M, Winkelmann W, Zoubek A, Kotz R: Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudien-gruppe COSS an 925 Patienten. Klin Pädiatr 211:260-270, 1999
Franzius C, Bielack S, Sciuk J, Vollet B, Jürgens H, Schober O: High-activity Samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin-Nuclear Medicine 38:337-340, 1999
Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R: Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma.
Clin Orthop Relat Res 358:120-127, 1999
Nowak-Göttl U, Münchow N, Klippel U, Paulussen M, Bielack S, Ullrich K, Ehrenforth S: The course of fibrinolytic proteins in children with malignant bone tumors. Eur J Pediatr 159(Suppl3):S151-S153, 1999
Fuchs N, Bielack S, Epler D, Bieling P, Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K:
Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9:893-899, 1998
Bielack S, Beron G, Winkler K: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature. Cancer 80:516-518, 1997 (letter)
Bielack S, Erttmann R, Kempf-Bielack B, Winkler K: Influence of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties? Eur J Cancer 32A:1652-1660, 1996
Bielack S, Kempf-Bielack B, Winkler K: Osteosarcoma: Relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 15:683-684, 1996 (letter)
Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jürgens H, Treuner R, Romanowski R, Exner U, Kotz R, Winkler K: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848-858, 1996
Bielack S, Wulff B, Delling G, Göbel U, Kotz R, Ritter J, Winkler K: Osteosarcoma of the trunk treated by multimodal therapy: Experience of the cooperative osteosarcoma study group COSS. Med Pediatr Oncol 24:6-12, 1995
Beck JD, Winkler K, Niethammer D, Brandis M, Hertzberg H, von der Hardt K, Greil J, Überall MA, Rossi R, Lamprecht-Dinnessen A, Brämswig J, Kaatsch P, Michaelis J, Meier W, Hausdorf G, Bielack S, Dörr HG: Die Nachsorge der von einer Krebserkrankung geheilten Kinder und jungen Erwachsenen. Erste Empfehlungen der Arbeitsgemeinschaft Spätfolgen. Klin Pädiatr 207:186-192, 1995
Bielack S, Bieling P, Fuchs N, Winkler K: Kindliche Knochentumoren. Kinderkrankenschwester 12:114-116, 1993
Rehan N, Bieling P, Winkler P, Helmke K, Maas R, Baldini N, Heise U, Fuchs N, Winkler K: The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy. Klin Padiatr. 1993 Jul-Aug;205(4):200-9
Winkler K, Bieling P, Bielack S: Die Chemotherapie des Osteosarkoms.
Z Orthop Grenzgeb 130 285-289, 1992
Geidel S, Garn M, Grävinghoff L, Hausdorf G, Morf G, Bielack S, Knop J, Winkler K:
Kardiomyopathie nach Osteosarkombehandlung: ein Beitrag zur Kardiotoxizität von Adriamycin. Klin Pädiatr 203:257-261, 1991
Bieling P, Bielack S, Delling G, Jürgens H, Kotz R, Dose C, Astheimer H, Exner G, Gadner H, Graf N, Ritter J, Salzer-Kuntschik M, Weinel P, Winkler K:
Neoadjuvante Chemotherapie des Osteosarkoms. Vorläufige Ergebnisse der kooperativen Studie COSS-86. Klin Pädiatr 203:220-230, 1991
Winkler K, Bieling P, Bielack S, Beron G, Delling G, Dose C, Jürgens H, Kotz R, Ritter J, Salzer-Kuntschik M: Local control and survival from the cooperative osteosarcoma group studies of the German society of pediatric oncology (GPO) and the Vienna bone tumour registry. Clin Orthop Relat Res 270:79-86, 1991
Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Kotz R, Greenshaw C, Jürgens H, Ritter J, Kusnierz-Glaz C, Erttmann R, Gädicke G, Graf N, Ladenstein R, Leyvraz S, Mertens R, Weinel P: Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS 86).
Cancer 66:1703-1710, 1990
Winkler K, Bielack S, Bieling P: Osteosarcoma. Curr Opin Oncol 2:486-490, 1990
Delling G, Pompesius-Kempa M, Welkerling H, Dreyer T, Maas R, Heise U, Winkler K: Morphological investigation of tumor growth and distribution of viable tumour areas in osteosarcomas after chemotherapy. Chir Organi Mov. 1990;75(1 Suppl):45-7
Knop J, Delling G, Heise U, Winkler K Parametric imaging of 99mTc methylene diphosphonate biokinetics in osteosarcoma for preoperative evaluation of chemotherapy-induced necrosis. Chir Organi Mov. 1990;75(1 Suppl):36-7.
Knop J, Delling G, Heise U, Winkler K: Scintigraphic evaluation of tumor regression during preoperative chemotherapy of osteosarcoma. Correlation of 99mTc-methylene diphosphonate parametric imaging with surgical histopathology. Skeletal Radiol. 1990;19(3):165-72
Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Purfurst C, Heise U, Jürgens H, Kotz R, Gadner H, Ritter J, et-al: Intensified chemotherapy with ifosfamide (IFO) and influence of intraarterial (i.a.) versus intravenous (i.v.) infusion of cisplatinum (DDP). Preliminary results. Chir Organi Mov 75:54-56, 1990
Winkler K, Torggler S, Beron G, Bode U, Gerein V, Jürgens H, Kusnierz-Glaz C, Kotz R, Salzer-Kuntschik M, Schmoll HJ, et al.: Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative osteosarcoma studies COSS-80 and COSS-82. Onkologie. 1989 Apr;12(2):92-6.
Bielack S, Erttmann R, Looft G, Purfürst C, Delling G, Winkler K, Landbeck G:
Platinum disposition after intraarterial and intravenous infusion of cisplatinum for osteosarcoma. Cancer Chemother Pharmacol 24:376-380 1989
Bielack S, Beck J, Delling G, Gerein V, Grümayer R, Hiddemann W, Jobke A, Jürgens H, Kornhuber G, Kotz R, Kusnierz-Glaz C, Ritschl P, Ritter J, Russe W, Salzer-Kuntschik M, Schellong G, Schmoll HJ, Steinhoff A, Winkelmann W, Winkler K: Neoadjuvante Chemotherapie des Osteosarkoms. Ergebnisse der kooperativen Studien COSS-80 und COSS-82 nach 7 bzw. 5 Jahren. Klin Pädiatr 201:275-284, 1989
Bielack S, Knop J, Delling G, Winkler K: Szintigraphische Verlaufskontrolle von Osteosarkomen während neoadjuvanter Chemotherapie. Ergebnisse der Cooperativen Osteosarkomstudien COSS der Gesellschaft für Pädiatrische Onkologie (GPO). Nuklearmedizin – Nuclear Medicine 27:237-241, 1988
Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, et al.: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37
Winkler K, Bielack S: Chemotherapy for Osteosarcoma. Semin Orthop 3(1): 48-58, 1988
Winkler K, Jürgens H, Treuner J: Neoadjuvant chemotherapy of sarcoma. The experiences of the German Society for Pediatric Oncology studies on osteosarcoma, Ewing's sarcoma and rhabdomyosarcoma. Dtsch Med Wochenschr. 1987 Sep 4;112(36):1385-90
Sommer HJ, Knop J, Heise U, Winkler K, Delling G: Histomorphometric changes of osteosarcoma after chemotherapy. Correlation with 99mTc methylene diphosphonate functional imaging. Cancer. 1987 Jan 15;59(2):252-8
Kersjes W, Heise U, Winkler K, Delling G: Comparison of quantitative ground substance analysis in biopsy and resected tumour in osteosarcomas.
Virchows Arch A Pathol Anat Histopathol. 1987
Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U, et al.: Effect of a local surgical procedure on the incidence of metastases following neoadjuvant chemotherapy of osteosarcoma.
Z Orthop Ihre Grenzgeb. 1986 Jan-Feb;124(1):22-9
Erttmann R, Bielack S, Landbeck G: Determination of 7-hydroxy-methotrexate in human plasma by reversed phase high-performance liqid chromatography.
Oncology 43:86-88 1986
Erttmann R, Bielack S, Landbeck G: 7-hydroxy-methotrexate and clinical toxicity.
J Cancer Res Clin Oncol 109:86-88, 1985
Erttmann R, Bielack S, Landbeck G: Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy. Cancer Chemother Pharmacol 15:101-104, 1985
Purfürst C, Beron G, Torggler S, Kotz R, Salzer-Kuntschik M, Winkler K.
Results of the COSS-77 and COSS-80 studies on adjuvant chemotherapy in osteosarcoma of the extremities. Klin Padiatr. 1985 May-Jun;197(3):233-8.
Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U, et al.: Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984 Jun;2(6):617-24
Jürgens H, Beron G, Winkler K: Toxicity associated with combination chemotherapy for osteosarcoma: a report of the cooperative osteosarcoma study (COSS 80). J Cancer Res Clin Oncol. 1983;106 Suppl:14-8
Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U, Havers W, Henze G, Hinderfield L, Höcker P, Jobke A, Jürgens H, Kabisch H, Landbeck G, Preusser P, Prindull G, Ramach W, Ritter J, Sekera J, Treuner J, Wüst G: Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study. J Cancer Res Clin Oncol. 1983;106 Suppl:1-7
Winkler K, Beron G, Schellong G, Stollmann B, Prindull G, Lasson U, Brandeis W, Henze G, Ritter J, Russe W, Stengel-Rutkowski L, Treuner J, Landbeck G: Cooperative osteosarcoma study COSS-77: results after 4 years. Klin Padiatr. 1982 Jul-Aug;194(4):251-6.